New ACS Guidance on Prostate Cancer Screening

Prostate cancer screening guidance is changing. Reports indicate that the American Cancer Society (ACS) now emphasizes regular, individualized screening discussions or screening for appropriate patients rather than treating prostate-specific antigen (PSA) testing as a one-time decision.

Screening can detect prostate cancer before symptoms develop. It can also produce false-positive results, unnecessary biopsies, overdiagnosis, and treatment-related side effects. The practical questions are when testing makes sense, how often it should occur, and what should happen after an abnormal result.

Screening decisions depend on age, overall health, life expectancy, family history, ancestry, inherited risk, previous PSA results, and personal preferences. Men considering screening should discuss these factors with a healthcare professional.

Publication fact-check: The supplied reports describe an ACS update but do not provide the official recommendation’s exact age thresholds, testing intervals, stopping criteria, or risk-group categories. One supplied summary identifies a CBS News report dated November 12, 2026. That date and the final ACS document should be verified before publication.

What the Updated Guidance Says

Available reports describe a shift toward regular screening discussions or screening for appropriate patients. This does not automatically mean that every man should receive an annual PSA test. A recommendation to discuss screening differs from a recommendation to undergo routine testing.

The final ACS language should be confirmed before publishing specific age ranges, testing schedules, or recommendations for higher-risk groups.

Three distinct steps

• Screening discussion: A conversation about individual risk, potential benefits, limitations, and preferences.
• PSA testing: A blood test that measures prostate-specific antigen in the blood.
• Follow-up evaluation: Additional testing or specialist assessment after an elevated, rising, or otherwise concerning result.

Screening recommendations evolve as evidence changes. Research continues to examine earlier detection, PSA limitations, prostate MRI, biomarker tests, biopsy strategies, and active surveillance for lower-risk disease.

The central challenge is identifying cancers likely to grow or spread while limiting unnecessary diagnosis and treatment of cancers that might never cause harm. Regular, risk-based monitoring may help clinicians assess PSA changes over time rather than relying on a single measurement.

Who Should Consider Screening?

Men at average risk

Average-risk men generally do not have a strong family history, a known inherited cancer-risk variant, or another factor associated with substantially increased risk. Age and overall health still influence whether screening is useful.

Screening may provide less benefit for men with limited life expectancy or serious illnesses that would make treatment difficult or unlikely to improve survival. A healthy older man and an older man with several serious medical conditions may face very different decisions.

Men at higher risk

Risk may be higher for men who have:

• A close relative with prostate cancer
• Several affected relatives
• A relative diagnosed at a young age
• A family history of aggressive or advanced prostate cancer
• Black or African American ancestry, if identified as a higher-risk group in the applicable guideline
• An inherited genetic variant associated with prostate or related cancers

Higher-risk men may need an earlier or more detailed screening discussion. The exact groups, ages, and testing schedules in the ACS update require confirmation against the official document.

Men with a family history

Patients should tell a clinician:

• Which relative had prostate cancer
• The relative’s age at diagnosis
• Whether the cancer was aggressive, metastatic, or fatal
• Whether more than one relative was affected
• Whether relatives had breast, ovarian, pancreatic, colorectal, or other related cancers

This information can help clinicians estimate risk and determine whether genetic counseling may be appropriate.

Men with genetic risk

Some inherited variants increase the risk of prostate cancer or aggressive disease. A strong family history of prostate, breast, ovarian, pancreatic, or related cancers may justify a discussion about genetic counseling.

Genetic testing is not necessary for every man. A counselor or clinician can assess the family pattern, explain possible results, and discuss how testing could affect screening and relatives.

How Screening Works

The PSA blood test

PSA is a protein produced by prostate cells. A PSA test measures its concentration in the blood.

An elevated PSA does not automatically indicate prostate cancer. PSA can increase because of:

• Benign prostate enlargement
• Prostatitis or other inflammation
• Urinary infection
• Recent ejaculation
• Certain medical procedures
• Urinary retention or irritation

Clinicians interpret PSA results in context. A single elevated result may lead to a repeat test rather than an immediate biopsy. The evaluation may also include medications, recent infections, urinary symptoms, and previous PSA measurements.

A normal PSA result does not guarantee that cancer is absent. No screening test detects every cancer, and PSA levels can change over time.

Digital rectal examination

During a digital rectal examination, a clinician feels the prostate through the rectal wall. The examination may identify unusual firmness, asymmetry, or nodules.

Its role varies by patient and guideline. It may complement PSA testing but should not be described as a universal replacement unless the verified ACS guidance specifically supports that approach.

Follow-up after an abnormal result

An abnormal or rising PSA result requires interpretation, not an automatic cancer diagnosis. Possible next steps include:

• Repeating the PSA test
• Reviewing recent infection, ejaculation, procedures, and medications
• Assessing PSA patterns over time
• Considering PSA density or velocity when clinically appropriate
• Ordering an additional biomarker test
• Using prostate MRI
• Referring the patient to a urologist
• Considering a biopsy

The appropriate next step depends on PSA level, prostate size, examination findings, family history, age, previous results, and the estimated likelihood of clinically significant cancer.

Potential Benefits

Screening can detect prostate cancer before symptoms develop. Earlier detection may provide more treatment choices when cancer is likely to grow or spread.

A prostate cancer diagnosis does not always require immediate treatment. Some cancers grow slowly and may be managed with active surveillance.

Treatment options may include:

• Active surveillance
• Surgery
• Radiation therapy
• Hormone-based treatment
• Other treatments based on cancer risk and stage

Decisions depend on grade, stage, PSA level, imaging, biopsy findings, overall health, and personal preferences. Screening should support informed decisions rather than pressure patients toward a specific treatment.

Potential Harms and Limitations

False-positive results

A false-positive result occurs when a screening test appears abnormal even though cancer is not present. An elevated PSA may cause anxiety and lead to repeat testing, imaging, specialist visits, or biopsy.

Biopsy risks

A prostate biopsy can cause pain or discomfort, bleeding in the urine, semen, or stool, infection, fever, and temporary urinary problems. MRI and biomarker tests may help some patients avoid unnecessary biopsy, although they do not eliminate uncertainty.

Overdiagnosis and overtreatment

Overdiagnosis means finding a cancer that would not have caused symptoms or shortened a person’s life. Overtreatment occurs when that cancer is treated despite little expected benefit.

Treatment can cause temporary or lasting side effects, including urinary incontinence, erectile dysfunction, bowel problems, and fertility-related concerns. Active surveillance may be appropriate for some lower-risk cancers and involves structured monitoring with treatment considered if the disease progresses.

A normal PSA does not rule out cancer. Men with persistent or concerning symptoms should seek medical care even after a normal screening result.

When to Talk With a Doctor

Before an appointment, gather:

• Age and general health history
• Family cancer history
• Previous PSA results
• Current medications
• Recent urinary symptoms or infections
• Prior prostate procedures
• Genetic testing results, if available

Useful questions include:

• What is my personal risk of prostate cancer?
• When should I begin screening?
• How often should I repeat the PSA test?
• Do I need a digital rectal examination?
• What could cause an elevated PSA result?
• What would happen if my PSA were abnormal?
• Would MRI or a biomarker test be useful?
• Should I consider genetic counseling or testing?
• When would screening provide little meaningful benefit?

Symptoms requiring medical attention

Seek medical advice for:

• Difficulty urinating
• A weak or interrupted urine stream
• Blood in the urine or semen
• Persistent pelvic or back pain
• Bone pain
• Unexplained weight loss

These symptoms can have causes other than prostate cancer, but they should not be ignored. Screening is intended for people without symptoms and does not replace diagnostic evaluation.

How Often Should Screening Occur?

The appropriate interval may depend on:

• Initial PSA level
• Age
• Family history
• Inherited risk
• Race or ancestry
• Previous abnormal results
• Overall health and life expectancy

A lower PSA may support a longer interval, while a higher or changing PSA may require earlier reassessment. The interval should be agreed upon with a clinician.

The available summaries do not provide a verified universal annual or multiyear schedule. Publishing a specific interval before reviewing the official ACS guidance could mislead readers.

How the Guidance Fits With Other Recommendations

Medical organizations may differ on:

• The age to begin screening
• Whether to recommend routine PSA testing
• Testing intervals
• Screening in older adults
• Higher-risk groups
• When screening should stop

Clinicians may consider ACS guidance alongside national recommendations, current evidence, medical history, life expectancy, and patient preferences. The update does not eliminate concerns about overdiagnosis or overtreatment.

Practical Takeaways

• Men who have never had a PSA test: Schedule a risk-based discussion with a primary care clinician and review potential benefits, harms, and follow-up procedures.
• Men who already receive regular screening: Continue the current plan until discussing the updated guidance with a clinician. Review whether the interval remains appropriate.
• Men with an elevated PSA: Do not assume that the result confirms cancer. Ask whether repeat testing, MRI, biomarkers, or urology referral is appropriate.
• Older men or men with serious health conditions: Discuss whether screening is likely to provide meaningful benefit, considering life expectancy, treatment tolerance, competing illnesses, and personal priorities.

Conclusion

Reports indicate that the American Cancer Society has updated its prostate cancer screening guidance and placed greater emphasis on regular, individualized screening discussions or screening for appropriate patients.

The key decision is not simply whether to test. It is when to test, how often to test, how to interpret the result, and what follow-up is appropriate.

The exact age thresholds, intervals, stopping criteria, and high-risk recommendations should be confirmed in the official ACS guideline before clinical decisions are made.

Frequently Asked Questions

What is the new ACS recommendation for prostate cancer screening?

Available reports indicate that the ACS updated its guidance and supports regular screening discussions or screening for appropriate patients. The exact age thresholds, risk categories, and testing intervals require verification against the official guideline.

Does regular screening mean an annual PSA test?

Not necessarily. The interval may depend on PSA results, age, family history, inherited risk, overall health, and personal preferences.

Who has a higher risk of prostate cancer?

Higher-risk groups may include men with a close family history, certain inherited variants, and groups identified by clinical guidelines as having higher incidence or mortality rates. The exact ACS categories should be confirmed in the final guideline.

Does an elevated PSA mean prostate cancer?

No. Benign prostate enlargement, inflammation, infection, recent ejaculation, and certain procedures can raise PSA. A clinician may repeat the test or order additional evaluation before recommending biopsy.

What are the disadvantages of screening?

Screening can cause false-positive results, anxiety, unnecessary biopsies, overdiagnosis, and overtreatment. Treatment may cause urinary, sexual, bowel, or fertility-related side effects.

Should men with urinary symptoms wait for routine screening?

No. Difficulty urinating, blood in the urine or semen, persistent pelvic or back pain, bone pain, or unexplained weight loss should be evaluated by a healthcare professional. Screening does not replace diagnostic assessment.